Neurona Therapeutics Presents Positive Clinical Update: New Data from NRTX-1001 Cell Therapy Trial in Drug-Resistant Epilepsy Announced at 2024 Annual Meeting of the American Epilepsy Society
06 déc. 2024 12h00 HE
|
Neurona Therapeutics
Neurona Therapeutics Presents Positive Clinical Update:
New Data from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy Announced at 2024 Annual Meet
Neurona Therapeutics Announces Participation in Upcoming Investor Conferences in October
27 sept. 2024 14h00 HE
|
Neurona Therapeutics
Neurona Therapeutics Announces Participation in Upcoming Investor Conferences in October
Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate
10 sept. 2024 16h05 HE
|
Neurona Therapeutics
Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate
Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs
26 juin 2024 16h05 HE
|
Neurona Therapeutics
Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs
Neurona Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for NRTX-1001 in Focal Epilepsy
18 juin 2024 16h05 HE
|
Neurona Therapeutics
- RMAT designation follows positive data update from the ongoing Phase 1/2 clinical trial of NRTX-1001 cell therapy, demonstrating a favorable safety profile to date and the potential to significantly...
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer
11 juin 2024 16h05 HE
|
Neurona Therapeutics
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer
Neurona Therapeutics to Participate in Jefferies Global Healthcare Conference
28 mai 2024 08h00 HE
|
Neurona Therapeutics
Neurona Therapeutics to Participate in Jefferies Global Healthcare Conference
Neurona Therapeutics Presents Positive Clinical Update from NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2024 Annual Meeting
15 avr. 2024 08h00 HE
|
Neurona Therapeutics
NRTX-1001 administration has been well-tolerated in all individuals treated to date 4 of 5 subjects treated with the lower dose of NRTX-1001 report >50% seizure reduction 3 of 5 subjects report...
Neurona Therapeutics to Present at Stifel 2024 Virtual CNS Days
12 mars 2024 16h00 HE
|
Neurona Therapeutics
SAN FRANCISCO, March 12, 2024 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological...
Neurona Therapeutics Announces Presentation of Updated Clinical Data at the Upcoming American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001
07 mars 2024 16h00 HE
|
Neurona Therapeutics
Neurona Therapeutics to present updated clinical data from NRTX-1001 investigational cell therapy program at AAN Annual Meeting